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Globally, ~41 million people die from non-communicable diseases 
(NCDs) each year, with >85% of deaths occurring in low- and 
middle-income countries (LMICs), including South Africa (SA). [1] 
In SA, 39% of total deaths in 2010 were due to NCDs, with the 
number of deaths similar to deaths from the combination of HIV 
and tuberculosis.[2] It is projected that in LMICs the number of 
deaths from NCDs will be five times higher than the number of 
deaths from communicable diseases by the year 2030.[3] Most deaths 
occur in the productive years, compromising the developmental 
goals defined by the World Health Organization (WHO), which 
include economic stability, poverty reduction and health equity. [4] 
The major NCD burden in LMICs is made up of hypertension, 
cardiovascular diseases, chronic lung diseases, type 2 diabetes, cancer 
and depression, all of which increase with age.[5] Risk factors such as 
alcohol consumption, smoking, dietary factors, lack of exercise and 
excess weight are responsible for a large share of the global disease 
burden, mediated directly or through conditions such as increased 
weight/body mass index (BMI), high blood pressure (BP), and 
elevated cholesterol and blood glucose levels.[6] It is worrisome that 
in SA this rapidly increasing NCD burden is occurring at the same 
time as the large number of HIV-positive individuals well managed 
on antiretroviral treatment is ageing.[7,8]
Cancer is one of the major causes of morbidity and mortality 
globally, with an estimated 14.9 million incident cases and ~8.2 
million cancer deaths in 2013 making cancer among the leading 
causes of death globally.[9] According to the WHO, cancer is the 
second leading cause of NCD deaths, accounting for 21% of all NCD 
deaths.[10] Breast cancer remains the most common cancer among 
women worldwide and is a major contributor to women’s cancer 
deaths. In LMICs the mortality-to-incidence ratios are comparatively 
high, mainly owing to advanced stage at diagnosis and suboptimal 
management.[11] Countries in sub-Saharan Africa, including SA, have 
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Background. Comorbidities occurring concurrently in breast cancer patients can be burdensome, as they may negatively influence time 
and stage of presentation.
Objectives. To describe the comorbid health conditions among South African (SA) black women with and without breast cancer and to 
determine factors associated with advanced-stage presentation of breast cancer.
Methods. A population-based case-control study on breast cancer was conducted in black women in Soweto, SA, the SABC (South Africa 
Breast Cancer) study. Lifestyle information and blood samples were collected from 399 women with histologically confirmed new cases of 
invasive primary breast cancer, recruited prior to any therapy, and 399 age- and neighbourhood-matched controls without breast cancer. We 
compared self-reported metabolic diseases, depression, anthropometric measurements, blood pressure, HIV status and point-of-care lipid 
and glucose levels between patients with breast cancer and the control group.
Results. In the whole population, the mean (standard deviation) age was 54.6 (12.9) years, the majority (81.2%) of the participants were 
overweight or obese, 85.3% had abdominal adiposity, 61.3% were hypertensive, 47.1% had impaired fasting plasma glucose, 8.4% had 
elevated total cholesterol, 74.8% had low high-density lipoprotein and 10.9% were assessed to be depressed. Ninety-one percent of the 
whole cohort had at least one metabolic disease. In the breast cancer group, 72.2% had one or more metabolic diseases only (HIV-negative 
and no evidence of depression), compared with 64.7% of the control group. From a multivariate logistic regression adjusted model, 
higher household socioeconomic status conferred a 19% reduction in the odds of having advanced-stage breast cancer at diagnosis, while 
hypertension, dyslipidaemia and HIV were not significantly associated with stage at breast cancer diagnosis in the adjusted model.
Conclusions. A large proportion of women experience several comorbidities, highlighting the need to address the chronic non-
communicable disease epidemic in SA and to co-ordinate multidisciplinary primary-, secondary- and tertiary-level care in the country’s 
complex healthcare system for better outcome.
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yet to identify cancer as a priority, allocating limited resources mainly 
to HIV, tuberculosis and other infectious disease management,[12-17] 
although the burden of cancer and NCDs in this region is increasing 
rapidly.[18]
Existing lifestyle risk factors and the metabolic syndrome (high 
blood glucose, high BP, abnormal cholesterol levels and excess fat 
around the waist) have been associated with increased breast cancer 
risk, especially in postmenopausal women.[19-22] Studies in LMICs 
have shown that the prevalence of the metabolic syndrome in breast 
cancer patients can be as high as 40%.[21] It has also been reported that 
about a third of women with breast cancer are likely to experience 
psychological distress.[23] Studies have shown that the prevalence of 
anxiety and depression ranges from 1.5% to 50% among women with 
breast cancer, depending on definitions and methods of assessment 
of psychological disorders.[24,25]
There have been conflicting reports on the association of education 
with breast cancer. Older studies have shown that women with 
higher education are at an increased risk of developing breast cancer 
compared with those with low education.[26-28] However, studies 
conducted in LMICs have reported the reverse.[29,30]
Studies have shown that stage at cancer diagnosis is affected by 
other health conditions, but the direction and magnitude of this 
effect are highly inconsistent.[31] Several competing mechanisms such 
as the surveillance hypothesis, psychological hypothesis, competing-
demand hypothesis and death-from-other-cause hypothesis may 
affect stage at diagnosis.[32]
The interplay between metabolic diseases, depression, HIV and 
breast cancer influences cancer treatment decisions and patients’ 
tolerance of and adherence to treatment.[33,34] Furthermore, the 
pres ence of metabolic diseases, depression and HIV has also been 
reported to negatively influence survival in breast cancer patients. [34-37] 
Metabolic diseases are largely preventable by eliminating risk factors 
such as harmful alcohol use, tobacco use, physical inactivity and an 
unhealthy diet. Better understanding of the prevalence of metabolic 
diseases, depression and HIV in SA populations is needed to improve 
health policies and service integration.[38]
Objectives
We conducted a population-based case-control study primarily 
to describe and compare the burden of metabolic diseases, HIV 
infection and depression in women with and without breast 
cancer. However, because the covariates analysed could possibly 
be associated with stage at breast cancer diagnosis, we analysed 
these covariates further to determine their effect on stage at 
diagnosis. The objectives of this study were to describe and compare 
the burden of metabolic diseases, depression and HIV among 
women newly diagnosed with invasive breast cancer at Chris Hani 
Baragwanath Academic Hospital (CHBAH), Soweto, SA, with that 
in age- and residential neighbourhood-matched controls, and to 
determine factors associated with advanced-stage breast cancer 
diagnosis.
Methods
Study design and setting
The SABC (South Africa Breast Cancer) study is a population-based 
case-control study set up in Soweto, home to a high-density urban 
population, to study the aetiology of breast cancer in SA black 
women. The SABC study is co-ordinated by the International Agency 
for Research on Cancer in collaboration with the University of the 
Witwatersrand, CHBAH, North-West University and the University 
of Southampton.
Women were recruited at the Breast Unit of CHBAH between 
December 2014 and June 2017. CHBAH is the largest public hospital 
in SA with >90% of patients being black, and it boasts an infrastructure 
with pathology laboratory services and professional skills that are 
not easily available in other African settings. Approximately 85% 
of patients presenting to CHBAH are referred from public sector 
primary- and secondary-care facilities within a 30 - 60 km radius, 
and the rest are either self-referred or referred from private general 
practitioners. Controls were recruited from the same communities 
as the cases.
Recruitment of cases and controls
Eligibility criteria
Cases. Women aged ≥18 years with histologically confirmed newly 
diagnosed breast cancer who provided written consent and met all 
the inclusion and exclusion criteria were enrolled. Exclusion criteria 
were pregnancy or breastfeeding, chronic renal disease, a previous 
cancer diagnosis or inability to answer questions.
Controls. Women aged ≥18 years who matched the cases for 
age (±5 years) and area of residence were selected from the Soweto 
population. Controls were recruited by community volunteers at 
churches and community centres.
For all subjects, fasting blood samples were collected prior to the 
start of any treatment (for cases), fractionated into serum, plasma, 
red blood cells and buffy coats, and stored at –80°C. At the same 
time, spot urine samples were collected from all subjects, aliquoted 
and stored at –80°C.
Procedures
Interviews
Investigators and trained study staff conducted face-to-face inter-
views. We collected detailed information on socioeconomic status 
(SES) during infancy and early childhood, health and reproductive 
history (number of births, age at each birth, age at menarche, 
and duration of breastfeeding for each birth), history of benign 
breast disease, use of exogenous hormones, smoking habits, alcohol 
intake, maximum attained body weight, body silhouette at different 
ages, physical activity (household and recreational) and hours per 
day spent sedentary (e.g. watching television), diet, occupation, 
environmental exposures, ethnicity, and family history of cancer. In 
particular, self-reported demographics, comorbidities (hypertension, 
diabetes, cardiovascular disease, tuberculosis, hypercholesterolaemia 
and depression) and socioeconomic indicators (education level, 
household socioeconomic score determined from motor vehicle 
ownership and household possessions (refrigerator, microwave, 
cell phone and landline telephone, washing machine, bed, cooking 
facilities), with the score calculated as described in a footnote to 
Table 1) were collected. The Patient Health Questionnaire-9 (PHQ-9) 
was used to assess depression and other major depressive symptoms. 
Its validity has been tested in studies in SA and a similar study in 
Mexican women.[39-41] Only seven of the nine questions from the 
PHQ were used. The two questions ‘Feeling down, depressed or 
hopeless’ and ‘Moving or speaking so slowly that other people could 
have noticed’ were omitted because they did not perform well on test-
retest reliability assessments.[41]
Anthropometric data and other measurements
Body weight, standing and sitting height, and waist and hip 
circumferences were measured. Pulse and BP were measured 
according to the American Heart Association recommendations.[42] 
Participants were seated, and three consecutive readings were taken.
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Blood measurements
Fasting plasma glucose and lipids (total cholesterol (TC) and high-
density lipoprotein (HDL)) were measured enzymatically with a glucose 
oxidase method and cholesterol oxidase method, respectively, using the 
RX Daytona Plus (Randox, UK) automated clinical chemistry analyser 
method. The coefficient of variation for the laboratory technician was 
<2% for the assays. Cases and controls were measured in the same 
batch. HIV status was measured by either the HIV 1-2 rapid test (Alere 
Inc., USA) for the controls or an enzyme-linked immunosorbent assay 
(ELISA) through the National Health Laboratory Service for the cases, 
because the cases were enrolled through the clinic.
Comorbidity measurements and classifications
The main comorbidities measured were obesity, hyperlipidaemia, 
hyperglycaemia, hypertension, depression and HIV infection. Obesity 
was determined by calculating the BMI from the height and weight 
using the WHO obesity cut-offs. A BMI of <18.5 kg/m2 was categorised 
as underweight, 18.5 - 24.9 kg/m2 as normal, 25 - 29.9  kg/ m2 as 
Table 1. Sociodemographic profile and disease risk in women from the SABC study with and without breast cancer
Variables Total (N=798)
Participants
p-value
Breast cancer 
(N=399) Controls (N=399)
Age (years), mean (SD) 54.6 (12.9) 54.6 (12.8) 54.7 (12.9) 0.939 
Level of education, n (%)
Completion of primary education and below 167 (20.9) 97 (24.3) 70 (17.5) 0.023*†
Completion of secondary education 617 (77.3) 298 (74.7) 319 (80.0)
Some tertiary education 14 (1.8) 4 (1.0) 10 (2.5)
Household SES (assets score, 0 - 8‡), mean (SD) 5.4 (1.3) 5.4 (1.3) 5.5 (1.3) 0.182
BMI (kg/m2), n (%)
Underweight§ and normal (<24.9) 150 (18.8) 82 (20.5) 68 (17.0) 0.649
Overweight (25.0 - 29.9) 192 (24.1) 93 (23.3) 99 (24.8)
Obese (30.0 - 39.9) 215 (26.9) 105 (26.3) 110 (27.6)
Morbidly obese ( ≥40) 241 (30.2) 119 (29.8) 122 (30.6)
Waist circumference (cm), mean (SD) 94.6 (13.8) 93.4 (13.8) 95.9 (13.7) 0.009*
Abdominal adiposity (waist circumference in cm), n (%)
<80 117 (14.7) 64 (16.0) 53 (13.3) 0.271
≥80 681 (85.3) 335 (84.0) 346 (86.7)
Dyslipidaemia (TC and HDL in mmol/L), n (%)
TC ≤6.21 731 (91.6) 368 (92.2) 363 (91.0) 0.523
TC >6.21 67 (8.4) 31 (7.8) 36 (9.0)
HDL ≤1.3 597 (74.8) 310 (77.7) 287 (71.9) 0.061
HDL >1.3 201 (25.2) 89 (22.3) 112 (28.1)
Hypertension (BP reading alone in mmHg, patients hypertensive  
on medications excluded), n (%)
Normal BP (<120/<80) 167 (36.5) 84 (36.4) 83 (36.7) 0.323
Category 1 (120 - 139/80 - 89) 142 (31.1) 79 (34.2) 63 (27.9)
Category 2 (140 - 159/90 - 99) 99 (21.7) 43 (18.6) 56 (24.8)
Category 3 (≥160/≥100) 49 (10.7) 25 (10.8) 24 (10.6)
Hypertension (using either BP reading or medication use), n (%)
No 309 (38.7) 163 (40.8) 146 (36.6) 0.217
Yes 489 (61.3) 236 (59.2) 253 (63.4)
Fasting glucose (mmol/L), n (%)
≤5.5 422 (52.9) 212 (53.4) 210 (52.6) 0.828
>5.5 376 (47.1) 185 (46.6) 189 (47.4)
Missing 2 2 0
Risk of depression (using either PHQ-9 score or self-reported 
depression), n (%)
No 711 (89.1) 364 (91.2) 347 (87.0) 0.053
Yes 87 (10.9) 35 (8.8) 52 (13.0)
HIV status, n (%)
Negative 642 (80.5) 333 (83.5) 309 (77.4) 0.032*
Positive 156 (19.5) 66 (16.5) 90 (22.6)
SABC = South Africa Breast Cancer; SD = standard deviation; SES = socioeconomic status; BMI = body mass index; TC = total cholesterol; HDL = high-density lipoprotein; BP = blood pressure; 
PHQ-9 = Patient Health Questionnaire-9.
*Significant at p<0.05.
†Fisher’s exact test.
‡Household SES (assets) score determined from: motor vehicle = 1, refrigerator = 1, microwave = 1, land telephone = 1, washing machine = 1, cell phone = 1, bed = 1, gas/electric stove = 1  
(1 for yes, 0 for no).
§19 women were underweight.
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overweight, 30 - 39.9 kg/m2 as obese, and ≥40  kg/m2 as morbidly 
obese.[43] Dyslipidaemia was defined as a TC level of >6.21  mmol/L 
or an HDL level of <1.19 mmol/L, while a fasting glucose level of 
>5.5 mmol/L was considered to indicate impaired fasting glucose. [44,45] 
BP was calculated using the average between the second and third 
BP readings. Hypertension was defined using BP readings alone 
and categorised as normal blood pressure (systolic <120 mmHg 
and diastolic <80 mmHg), category 1 (systolic 120 - 139  mmHg 
or diastolic 80 - 89 mmHg), category 2 (systolic 140 - 159 mmHg 
or diastolic 90 - 99 mmHg) or category 3 (systolic ≥160 mmHg or 
diastolic ≥100 mmHg). [46] It was further defined as ‘No’ or ‘Yes’ (mean 
systolic BP of ≥140 mmHg or mean diastolic BP ≥90  mmHg, or 
normal BP with self-reported hypertensive medication use).
Outcome measurement
The primary outcome measurement was stage at breast cancer 
presentation to the CHBAH Breast Unit (early stage I and II v. 
advanced stage III and IV), which was extracted from the Breast 
Unit database. Stage was assessed clinically at diagnosis. It was 
primarily coded according to the tumour-node-metastasis (TNM) 
classification and then converted to Manchester staging.
Statistical analysis
Differences in demographics, socioeconomic factors, metabolic 
diseases, depression and HIV between the breast cancer and control 
groups were described and reported using Pearson’s χ2 and Fisher’s 
exact tests for categorical variables. Means and standard deviations 
(SDs) were computed for continuous variables using Student’s t-test 
to report differences between groups. Frequencies of metabolic 
diseases in the cohort were analysed and reported, and frequencies of 
metabolic diseases, depression and HIV in breast cancer patients were 
also analysed with stage at breast cancer diagnosis as the outcome 
variable. To examine associations with advanced-stage breast cancer, 
we used multivariable logistic regression models. Variables for 
which p-values were <0.1 in bivariate analysis were included in our 
multivariate models. Odds ratios (ORs) were examined in three 
models in our multivariate analysis, with r2 values (coefficient of 
determination) reported as explained variation. We added in a 
stepwise fashion sociodemographic factors (age and household SES), 
dyslipidaemia, hypertension and HIV to examine the association 
between these factors and advanced presentation of breast cancer. 
Analysis was performed using Stata version 14 (StataCorp, USA).
Ethical considerations
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. Ml40980) and the 
International Agency for Research on Cancer Ethics Committee (ref. 
no. IEC 12-38).
Results
A total of 798 women (399 cases and 399 controls) were correctly 
matched for both neighbourhood and age to within 5 years. In the 
first year of recruitment, controls were enrolled independently 
of case matching in accordance with a predictive recruitment 
algorithm developed from analysis of patients enrolled in a 
previous study.[47] The characteristics of the cohort are summarised 
in Table  1. The overall mean age (SD) was 54.6 (12.9) years. 
Educational level, HIV status and waist circumference differed 
significantly between the two groups. Women in the control group 
were more likely than the breast cancer patients to have schooling 
beyond primary education (p=0.023). Over a fifth (22.6%) of the 
women in the control group were HIV-positive, while the figure 
for the breast cancer group was 16.5% (p=0.032). The mean (SD) 
waist circumference in the control group was 95.9 (13.7) cm while 
that in the breast cancer group was 93.4 (13.7) cm (p=0.009). There 
were no significant differences in household SES, nutritional status 
(BMI), level of hypertension, dyslipidaemia, fasting plasma glucose 
or assessment of depression between the two groups. In the total 
cohort, the majority (81.2%) of the participants were overweight 
or obese, 85.3% (n=681) had abdominal adiposity, 8.4% (n=102) 
had elevated TC, 74.8% (n=597) had low HDL, 47.1% (376) had 
impaired fasting plasma glucose, 61.3% (n=489) were hypertensive, 
with 43.2% (n=341) on treatment, and 10.9% (n=87) were assessed 
to be depressed (Table 1).
In determining the number of metabolic diseases reported in 
the whole cohort, only 9% (n=72) of the women had no metabolic 
disease; 24.1% (n=192) had one metabolic disease, 38.1% (n=304) 
had two metabolic diseases, 24.7% (n=197) had three metabolic 
diseases and 4.1% (n=33) had four metabolic diseases (Table 2). 
There were no significant differences in the number of metabolic 
diseases between the cases and their controls (p=0.285).
When combining at least one metabolic disease, depression and 
HIV, 2.9% (n=23) of the women presented with these three diseases 
in the whole cohort, and this proportion was almost doubled in 
the control group (3.8%, n=15) compared with the breast cancer 
group (2.0%, n=8). The majority (72.2%, n=285) of the women in 
the breast cancer group and 64.7% (n=257) of those in the control 
group presented with metabolic diseases alone (HIV-negative and no 
evidence of depression).
Women with no metabolic disease, depression or HIV comprised 
5.8% (n=23) and 4.0% (n=16) of the breast cancer group and the 
control group, respectively. The distribution of metabolic diseases, 
depression and HIV was significantly different between the breast 
cancer and control groups (p=0.036) (Table 3).
In bivariate analysis, among women from the breast cancer group 
(Table 4) there was a 21% reduction in the odds of presenting with 
advanced-stage breast cancer for every unit increase in household 
Table 2. Frequency of metabolic diseases* in women from the SABC study, overall and by case/control status
Metabolic diseases, n Total (N=798), n (%) Breast cancer (N=399), n (%) Controls (N=399), n (%) p-value
0 72 (9.0) 42 (10.5) 30 (7.5) 0.285
1 192 (24.1) 101 (25.3) 91 (22.8)
2 304 (38.1) 139 (34.9) 165 (41.3)
3 197 (24.7) 99 (24.8) 98 (24.6)
4 33 (4.1) 18 (4.5) 15 (3.8)
Total 798 (100) 399 (100) 399 (100)
SABC = South Africa Breast Cancer.
*Defined as obesity (body mass index ≥30 kg/m2), dyslipidaemia (total cholesterol >6.21 mmol/L), hypertension (blood pressure ≥140/≥90 mmHg or medication use) and hyperglycaemia 
(fasting glucose >5.5 mmol/L).
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Table 3. Frequency of at least one metabolic disease,* depression and HIV in women from the SABC study, overall and by  
case/control status
At least one MD, D, HIV Total (N=798), n (%) Breast cancer (N=399), n (%) Controls (N=399), n (%) p-value
MD+, D–, HIV– 542 (68.4) 285 (72.2) 257 (64.7) 0.036
MD+, D–, HIV+ 103 (13.0) 41 (10.4) 62 (15.6)
MD+, D+, HIV– 58 (7.3) 23 (5.8) 35 (8.8)
MD–, D–, HIV+ 27 (3.4) 15 (3.8) 12 (3.0)
MD+, D+, HIV+ 23 (2.9) 8 (2.0) 15 (3.8)
MD–, D–, HIV– 39 (4.9) 23 (5.8) 16 (4.0)
Total 792 (100) 395 (100) 397 (100)
Not shown† 6 4 2
SABC = South Africa Breast Cancer; MD = metabolic disease; D = depression.
*Obesity, hyperlipidaemia, hypertension or hyperglycaemia.
†D+, MD–, HIV– and D+, HIV+, MD– combinations.
Table 4. Bivariate analysis of variables associated with advanced-stage presentation (stages III and IV) among women diagnosed 
with breast cancer at the Chris Hani Baragwanath Academic Hospital Breast Clinic in Soweto, South Africa
Variables
Bivariate analysis
OR (95% CI) p-value
Age (years) 0.99 (0.97 - 1.00) 0.162
Level of education
Completion of primary education and below 3.47 (0.35 -  34.51) 0.384
Completion of secondary education 2.77 (0.28 - 26.90)
Some tertiary education Reference
Household SES (asset score) 0.79 (0.67 - 0.92) 0.002*
BMI (kg/m2)
Underweight and normal (<24.9) Reference 0.343
Overweight (25.0 - 29.9) 0.80 (0.4 4 - 1.45)
Obese (30.0 - 39.9) 0.59 (0.33 - 1.05)
Morbidly obese ( ≥40) 0.74 (0.42 - 1.31)
Waist circumference 0.99 (0.98 - 1.00) 0.167
Abdominal adiposity (waist circumference in cm)
<80 1.41 (0.82 - 2.41) 0.212
≥80 Reference
Dyslipidaemia (TC and HDL in mmol/L)
TC ≤6.21 2.53 (1.13 - 5.63) 0.018*
TC >6.21 Reference
HDL ≤1.3 1.77 (1.09 - 2.87) 0.019*
HDL >1.3 Reference
Hypertension (BP reading alone in mmHg, patients hypertensive on  
medications excluded)
Normal (<120/<80) Reference 0.516
Category 1 (120 - 139/80 - 89) 1.15 (0.62 - 2.14)
Category 2 (140 - 159/90 - 99) 0.65 (0.31 - 1.37)
Category 3 (≥160/≥100) 0.89 (0.37 - 2.19)
Hypertension (using either BP reading or medication use)
No 1.64 (1.09 - 2.46) 0.015*
Yes Reference
Impaired fasting glucose (mmol/L)
≤5.5 Reference 0.217
>5.5 1.28 (0.86 - 1.90)
Risk of depression (using either PHQ-9 score or self-reported depression)
No 1.31 (0.65 - 2.66) 0.437
Yes Reference
HIV status
Negative Reference 0.041*
Positive 1.75 (1.01 - 2.99)
OR = odds ratio; CI = confidence interval; BMI = body mass index; TC = total cholesterol; HDL = high-density lipoprotein; BP = blood pressure; PHQ-9 = Patient Health Questionnaire-9.
*Significant at p<0.05.
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SES asset score (OR 0.79, 95% confidence interval (CI) 0.67 - 0.92). 
Women with a TC level ≤6.21 mmol/L and an HDL level ≤1.3 mmol/L 
had a higher risk of advanced-stage disease (OR 2.53, 95% CI 1.13 - 
5.63 and OR 1.77, 95% CI 1.09 - 2.87, respectively). Women who 
were HIV-positive but not hypertensive were also more likely to 
present with advanced-stage disease (OR 1.64, 95% CI 1.09 - 2.46 and 
OR 1.75, 95% CI 1.01 - 2.99, respectively). Variables significant in the 
bivariate analysis were further explored in individual and combined 
logistic regression models controlling for age (Table 5).
Sociodemographic factors (model 1) independently explained 
2.9% of the variance, and household SES was shown to partially 
influence the likelihood of advanced stage at diagnosis. Comorbid 
factors (model 2) explained 3.3% of the variance, with patients with 
no dyslipidaemia and patients with no hypertension having greater 
odds of advanced-stage presentation. In the final model with all 
factors included (model 3), 4.9% of the variance was explained. The 
associations of advanced-stage breast cancer with household SES 
were slightly attenuated on adjustment (OR 0.81, 95% CI 0.69 - 0.95), 
whereas associations with hypertension, dyslipidaemia and HIV were 
no longer significant in mutually adjusted models (Table 5).
Discussion
We found that there was a high burden of metabolic diseases, 
depression and HIV in women with and without breast cancer in 
Soweto. About two-thirds of the whole cohort had two or more 
metabolic diseases and 10.2% had at least one metabolic disease and 
depression. The prevalence of metabolic diseases and depression was 
comparable in women with breast cancer and those without.
Women with breast cancer had lower levels of education compared 
with their controls. There was a significant difference in waist 
circumference and HIV status between the two groups, while 
levels of obesity, hyperlipidaemia, hypertension, hyperglycaemia and 
depression were similar. The combination of at least one metabolic 
disease, depression and HIV differed between the breast cancer group 
and the control group. A higher household socioeconomic asset score 
was protective against advanced-stage breast cancer at presentation, 
while hypertension, dyslipidaemia and HIV had no significant 
influence on stage at presentation.
The study demonstrated that women with breast cancer were 
significantly less educated than their controls, supporting literature 
reports that showed less-educated women and women with low SES 
to be at increased risk of breast cancer.[29,30] The increased risk of breast 
cancer in less educated women is partly due to changes in reproductive 
factors and lifestyle modification. We reported a high prevalence of 
comorbidity among Soweto women in general, corroborating findings 
from previous studies in SA from various settings.[48,49] About one-fifth 
of our whole cohort were HIV-positive, while almost 14% of breast 
cancer patients with at least one metabolic disease and depression were 
also positive for HIV. This finding further supports the fact that our 
population is carrying a double burden involving an epidemiological 
overlap of NCDs and infectious diseases.
Studies have reported an association between metabolic diseases 
and risk of breast cancer, especially in postmenopausal women. [22,50] 
There was no significant difference in our study with regard to 
individual metabolic disease components (obesity, dyslipidaemia, 
hypertension and hyperglycaemia) or in the number of metabolic 
diseases with which women with and without breast cancer presented; 
however, the proportion of women presenting with metabolic diseases 
was so high in both groups that significant differences were difficult 
to detect. Several factors, such as physical activity, dietary intake, 
smoking and alcohol intake, could explain the high prevalence of 
metabolic diseases in our study, and these lifestyle behaviours will be 
the focus of a future article.
Women with higher SES tended to present with early-stage breast 
cancer disease. It has been reported that intention to seek medical 
care is not entirely dependent on education and SES but on complex 
personal and social factors and previous healthcare-seeking habits. [51] 
Appropriate targeted interventions to address inequalities evident 
in stage at breast cancer diagnosis may help in improving stage at 
diagnosis.
The cost of care of breast cancer patients with metabolic 
diseases, depression and HIV places a big burden on the limited 
Table 5. Multiple logistic regression models of factors influencing advanced-stage presentation (stages III and IV) among women 
diagnosed with breast cancer at the Chris Hani Baragwanath Academic Hospital Breast Clinic in Soweto, South Africa
Variables
Bivariate analysis
OR (95% CI)
Model 1, 
sociodemographic
OR (95% CI)
Model 2, 
comorbidities
OR (95% CI)
Model 3, 
sociodemographic + 
comorbidities
OR (95% CI)
Sociodemographic
Age in years 0.99 (0.97 - 1.00) 0.99 (0.97 - 1.00) 0.99 (0.98 - 1.02)
Household socioeconomic status (asset score) 0.79 (0.67 - 0.92)* 0.79 (0.67 - 0.92)* 0.81 (0.69 - 0.95)*
Comorbidities
Dyslipidaemia (TC in mmol/L)
≤6.21 2.53 (1.13 - 5.63)* 2.46 (1.10 - 5.54)* 2.18 (0.96 - 4.96)
>6.21 Reference Reference Reference
 Hypertension (using either BP reading or 
medication use)
No 1.64 (1.09 - 2.46)* 1.56 (1.04 - 2.35)* 1.50 (0.96 - 2.35)
Yes Reference Reference Reference
HIV status
Negative Reference Reference Reference
Positive 1.75 (1.01 - 2.99)* 1.60 (0.93 - 2.77) 1.44 (0.80 - 2.57)
r2 0.0286* 0.0335* 0.0486*
OR = odds ratio; CI = confidence interval; TC = total cholesterol; BP = blood pressure.
*Significant at p<0.05.
270       April 2019, Vol. 109, No. 4
RESEARCH
healthcare resources in SA public hospitals. Controlling cost of 
care and significant patient out-of-pocket costs should be of great 
concern among public and private managers and policymakers. 
The integrated chronic disease management (ICDM) model was 
introduced as a response to the dual burden of HIV/AIDS and 
NCDs in SA. However, the aim for which the ICDM model was 
initiated, i.e. to use the HIV programme as leverage for scaling 
up services for NCDs, is yet to be achieved.[52] The majority 
of patients experiencing multiple comorbidities visit healthcare 
facilities frequently. Navigation and co-ordination of care in these 
patients can be very difficult, and ultimately they are vulnerable to 
suboptimal quality of care. Our results highlight the necessity for 
health system integration of services and continuity of care.[53] The 
management of breast cancer patients also burdened with metabolic 
diseases, depression and HIV may result in further fragmentation of 
care, as cancer treatment is complex and multidisciplinary in nature. 
It is therefore essential for patient management to extend beyond the 
cancer domain and include the high burden of other communicable 
and non-communicable diseases. Co-ordination and integration of 
care for cancer and other comorbid conditions is fundamental to 
cost-effective healthcare delivery for patients and health systems 
alike, as previously identified. [54,55] Shared hospital appointments, 
community-based cancer care and collaboration with primary 
healthcare services may all be helpful in improving co-ordination of 
care for breast cancer patients and may improve survival outcomes 
in these patients.
Poor quality of life and survival among women with breast cancer 
may be exacerbated by multiple comorbidities.[56] Other factors that 
may adversely affect outcome include large out-of-pocket expenses 
such as transport costs and loss of wages and employment that may 
result in poor adherence to multiple treatments and adverse drug 
interactions that may affect cancer treatment efficacy and tolerance. 
Breast cancer patients with comorbidities are more likely than 
those without to experience adverse outcomes as a result of non-
completion of radiation therapy and are less likely to initiate and 
complete chemotherapy.[57,58]
Study limitations
The limitations to this study include the fact that it was conducted in 
Soweto, which means that our findings may not be generalisable to 
the whole population of SA. Some bias is possible in our recruitment 
and exposure assessment, but our participation rate was high 
(91.3%) and women were not aware of our research hypothesis. 
Any misclassification is therefore probably random. Simultaneous 
testing of several hypotheses was carried out in our analysis to assess 
differences in sociodemographic factors and metabolic diseases, 
depression and HIV across stage at breast cancer presentation. 
This could reduce the significance value to very precise levels and 
increases the chances of a false-negative error (type 2 error);[59] 
however, our focus was more on the actual effect size than the level 
of significance, and our analysis was focused on a single primary 
endpoint. Despite these limitations, knowledge gained from this 
study on the prevalence of metabolic diseases, depression and HIV in 
women from Soweto with and without breast cancer and our finding 
on the importance of the household socioeconomic asset score in 
relation to stage at breast cancer diagnosis highlight the need for 
better community awareness and screening for metabolic diseases, 
depression, HIV and other chronic disease, for further research 
on treatment compliance in patients with breast cancer, treatment 
tolerance and efficacy and survival outcomes, and for integration of 
care for multi-comorbidities.
Conclusions
Many SA women with breast cancer from socioeconomically 
disadvantaged communities are burdened with metabolic diseases, 
depression and HIV. There is a need for research on treatment 
efficacy and tolerance, and co-ordination of care for easier navigation 
in SA’s complex healthcare system.
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